Myriad Genetics MYGN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Hereditary Cancer | $372.4M+2.2% | $364.5M+11.2% | $327.8M— | —— | |
| Prenatal | $186.3M+5.2% | $177.1M+17.1% | $151.3M— | —— | |
| Revenue by Geography | |||||
| RoW | $56.5M-17.0% | $68.1M-16.4% | $81.5M-6.2% | $86.9M0.0% | |
| U.S. | $768M-0.2% | $769.5M+14.6% | $671.7M+13.6% | $591.5M-2.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Myriad Genetics break its business down?
- Myriad Genetics (MYGN) reports revenue by product across 5 parts — Cancer Care Continuum, Hereditary Cancer, Mental Health, Prenatal Health and Prenatal. Each is extracted from the segment footnotes and tracked over time.
- Where does Myriad Genetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Myriad Genetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
